Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;29(2):105-135.
doi: 10.1111/resp.14656. Epub 2024 Jan 11.

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

John A Mackintosh  1   2 , Gregory Keir  3 , Lauren K Troy  4   5 , Anne E Holland  2   6   7 , Christopher Grainge  8 , Daniel C Chambers  1   2 , Debra Sandford  2   9   10 , Helen E Jo  4   5 , Ian Glaspole  2   11 , Margaret Wilsher  12 , Nicole S L Goh  13   14   15 , Paul N Reynolds  2   9   10 , Sally Chapman  16 , Steven E Mutsaers  17 , Sally de Boer  12 , Susanne Webster  4 , Yuben Moodley  2   16   17 , Tamera J Corte  2   4   5
Affiliations

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

John A Mackintosh et al. Respirology. 2024 Feb.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.

Keywords: idiopathic pulmonary fibrosis; interstitial lung disease; progressive pulmonary fibrosis; pulmonary fibrosis; treatment.

PubMed Disclaimer

Conflict of interest statement

John A. Mackintosh—reports speaker fees from Boehringer Ingelheim, Gregory Keir—reports advisory board, travel and speaker fees from Boehringer Ingelheim and Roche, Lauren K. Troy—reports speaker fees from Boehringer Ingelheim and Erbe Elektromedezin, and advisory board roles for Boehringer Ingelheim and Roche, Anne E. Holland—reports no conflicts of interest, Christopher Grainge—reports being an investigator for clinical trials sponsored by Boehringer Ingelheim, Syneos and Roche; and reports contractual basic laboratory science conducted on behalf of Boehringer Ingelheim, Daniel C. Chambers—reports speaker fees from Boehringer Ingelheim, Debra Sandford—reports no conflicts of interest, Helen E. Jo—reports no conflicts of interest, Ian Glaspole—reports advisory board fees from Boehringer Ingelheim and consulting fees from Amplia, Accendatech, Lassen, Tianli, Ad Alta and Avalyn, Margaret Wilsher—reports speaker fees from Boehringer Ingelheim and investigator role for trials sponsored by Boehringer Ingelheim, Syneos and Roche, Nicole S. L. Goh—reports no conflicts of interest, Paul N. Reynolds—reports no conflicts of interest, Sally Chapman—reports no conflicts of interest, Steven E. Mutsaers—reports no conflicts of interest, Sally de Boer—reports no conflicts of interest, Susanne Webster—reports no conflicts of interest, Yuben Moodley—reports no conflicts of interest, Tamera J. Corte—reports personal fees for speaking commitments, travel and advisory board membership from Boehringer Ingelheim, Roche, and Bristol Myers Squibb, Vicore, Bridge Therapeutics, and DevPro, and institutional fees for unrestricted grants from Boehringer Ingelheim, Roche, Galapagos, Biogen, Bristol Myers Squibb and Actelion. Christopher Grainge, Debra Sandford, Paul N. Reynolds, Yuben Moodley and Tamera J. Corte are Editorial Board members of Respirology—they were excluded from all editorial decision‐making related to the acceptance of this article for publication.

Figures

FIGURE 1
FIGURE 1
Suggested algorithm for the management of IPF and PPF. *Subsidized prescribing criteria will vary depending on jurisdiction. Observation of fibrotic disease progression in an ILD other than IPF should prompt review of the disease specific management approach, consideration of re‐evaluation of the diagnosis at an ILD‐MDM and consideration of nintedanib should it be accessible. Enrolment in clinical trials should be considered for all patients with IPF and PPF. Alongside pharmacologic therapies, all ILD patients should be considered for supportive therapies as well as lung transplantation and palliative care where relevant. ILD, interstitial lung disease; MDM, multi‐disciplinary meeting; PPF, progressive pulmonary fibrosis.
FIGURE 2
FIGURE 2
Pathogenic pathways of IPF and potential clinical trial targets. Current (blue) and proposed (green) molecules assessed in clinical trials for the treatment of idiopathic pulmonary fibrosis. Modulators (→) and inhibitors (┬) are shown directed at different components of the fibrosis pathway. Created with Biorender.com.
FIGURE 3
FIGURE 3
Transplant window and the unpredictable natural history of IPF necessitating referral early in the disease course. Given the unpredictable nature of IPF, transplant referral should be strongly considered at the time of diagnosis. (A) Rapidly deteriorating patient, whose diagnosis and transplant window occurs synchronously with a subsequent very narrow transplant window. (B) *Acute‐exacerbation of IPF prompting rapid deterioration. Outcomes of transplantation in this context are worse. (C) Linear progression, enabling easier assessment of when transplant window opens. (D) Step‐wise deterioration, a period of stability may give a false sense of reassurance. (E) Slowly progressive disease that may never come to transplant. Figure adapted from Ley et al.
See this image and copyright information in PMC

References

    1. Jo HE, Troy LK, Keir G, Chambers DC, Holland A, Goh N, et al. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology. 2017;22(7):1436–1458. - PubMed
    1. Raghu G, Remy‐Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. - PMC - PubMed
    1. Cox IA, Otahal P, de Graaff B, Corte TJ, Moodley Y, Zappala C, et al. Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Respirology. 2022;27(3):209–216. - PubMed
    1. Zheng Q, Cox IA, Campbell JA, Xia Q, Otahal P, de Graaff B, et al. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta‐analysis. ERJ Open Res. 2022;8(1):00591‐02021. - PMC - PubMed
    1. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727. - PubMed

Publication types